linjc16/ctgov huggingface dataset:
The Observational Study of Growth Hormone-secreting Pituitary Tumors

Study Overview
=================
Brief Summary
-----------------
The major purpose of this study is to evaluate the changes of multiple organs in patients with growth hormone-secreting pituitary tumors before and after surgery. Plasma, DNA samples and pituitary tumor tissues will be kept for further analysis.

Detailed Description
-----------------
Multiple organs or systems will be affected by excessive growth hormones in patients with acromegaly. The major purpose of this study is to evaluate the changes before and after the pituitary surgery.

Official Title
-----------------
The Observational Study of the Structures and Functions of Multiple Organs in Patients With Growth Hormone-secreting Tumors

Conditions
-----------------
Acromegaly, Pituitary Tumor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of acromegaly > 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acromegaly, pituitary tumor
Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit

Study Overview
=================
Brief Summary
-----------------
The Stanford Tobacco Prevention Toolkit is a free, online Toolkit that consists of a curriculum, educational resources, and a resource directory to be used by educators, parents, juvenile justice workers, and healthcare providers to increase knowledge and awareness of cannabis and reduce use among youth. The aim of this study is to investigate the extent to which the curriculum changes students' intentions to use and actual use of cannabis.

Official Title
-----------------
Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit

Conditions
-----------------
Cannabis Use

Intervention / Treatment
-----------------
* Behavioral: Stanford Cannabis Awareness and Prevention curriculum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Middle school and high school students receiving health education at schools participating in the study Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Receives the Stanford Cannabis Prevention and Awareness curriculum<br>Stanford Cannabis Prevention and Awareness curriculum administered | Behavioral: Stanford Cannabis Awareness and Prevention curriculum<br>* Stanford Cannabis Awareness and Prevention curriculum delivered as a 5-session course administered in a school classroom setting.<br>|
| No Intervention: Does not receive Stanford Cannabis Prevention and Awareness curriculum<br>Receives another curriculum or no cannabis prevention curriculum | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in cannabis use | Investigator-originated survey measures (questions) assess ever cannabis use & past 30-day cannabis use. This outcome measure assesses cannabis use. | Change from baseline to follow-up at approximately 156 weeks | 
| Change in intention to use cannabis in the future | Investigator-originated survey measures (questions) assessing change in participant intention to use cannabis in the future | Change from baseline to follow-up at approximately 156 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
youth, cannabis, education, health, prevention, marijuana
Interaction Between Cocaine and Quetiapine - 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety of intravenous (IV) cocaine in subjects taking quetiapine at 3 dosage levels.

Detailed Description
-----------------
A placebo-controlled, double-blind, inpatient assessment of interaction between intravenous cocaine and quetiapine (seroquel) in cocaine-experienced subjects. To assess the safety of IV cocaine in subjects taking quetiapine at 3 dosage levels.

Official Title
-----------------
Interaction Between IV Cocaine and Quetiapine

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Quetiapine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Includes but is not limited to: non-treatment seeking individuals. Must meet DSM-IV criteria for cocaine abuse or dependence. Must be able to verbalize understanding of consent and provide written informed consent and verbalize willingness to complete study procedures. Site will provide further details. Exclusion Criteria: Please contact site for further information

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Quetiapine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events |  |  | 
| pharmacokinetic assessment |  |  |
The Effectiveness of Cow's Milk Immune Globulin in the Treatment of AIDS-Related Diarrhea

Study Overview
=================
Brief Summary
-----------------
To examine the efficacy of cow's milk immune globulin in the treatment of diarrhea due to chronic intestinal cryptosporidiosis in patients with AIDS. The secondary end points of the study involve functional improvement which will be determined from nutritional and absorption studies.

Official Title
-----------------
Efficacy of Cow's Milk Immune Globulin in the Treatment of Chronic Intestinal Cryptosporidiosis in Patients With AIDS

Conditions
-----------------
Cryptosporidiosis, HIV Infections

Intervention / Treatment
-----------------
* Drug: Cryptosporidium Immune Whey Protein Concentrate (Bovine)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: Diagnosis of diarrhea associated with intestinal cryptosporidiosis. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Survival time projected to be < 9 weeks. Inability to tolerate any oral intake. Known allergy or intolerance to milk products. Organic mental syndrome precluding informed consent or following directions. Patients with the following are excluded: Survival time projected to be < 9 weeks. Inability to tolerate any oral intake. Known allergy or intolerance to milk products. Organic mental syndrome precluding informed consent or following directions.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cryptosporidium Immune Whey Protein Concentrate (Bovine)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Assessment of Change in Atherosclerotic Plaque by Serial CCTA

Study Overview
=================
Brief Summary
-----------------
Assessment of Change in AtheROSclerotic Plaque by Serial CCTA (ACROSS) is designed as a prospective observational study which aim is to demonstrate the effect of statins on coronary atherosclerosis, assessed by quantitative analysis of CCTA.

Official Title
-----------------
Assessment of Change in Atherosclerotic Plaque by Serial CCTA

Conditions
-----------------
Coronary Artery Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Coronary Arteriosclerosis

Intervention / Treatment
-----------------
* Drug: Atorvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent clinically indicated CCTA (index CCTA) Mild to moderate stenosis (25-69%) on CCTA ≥1 clinical risk factors (Smoking, HTN, HDL<40, Premature FHx, M ≥45, F ≥55) for CAD Exclusion Criteria: Acute coronary syndrome (unstable angina or MI) Positive (not equivocal) stress test Contraindications to statin

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Atorvastatin|Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in percent change of total atheroma volume assessed by CCTA between statin-taking and statin-naïve group | Patients indicated with statin therapy according to current guideline will receive atorvastatin. | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of total atheroma volume at 24 months compared with baseline total atheroma volume | total atheroma volume assessed by CCTA | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary artery disease, coronary computed tomography angiography, statins, coronary atherosclerosis
Hip Strength and Nerve Palsy After the Modified Stoppa Approach to Acetabular Fracture Reduction and Fixation

Study Overview
=================
Brief Summary
-----------------
The purpose of this prospective study is to compare hip adductor strength and obturator nerve palsy between acetabular fracture patients whose fracture was reduced and fixated using the modified Stoppa approach (subjects) and pelvic fracture patients (controls) using physical strength testing, radiographs, clinical assessment, and a validated functional outcome questionnaire. The investigators' research hypothesis is that there will be less strength and higher incidence of obturator nerve palsy in patients treated with the modified Stoppa approach (intervention) than in patients treated without the modified Stoppa approach (controls).

Official Title
-----------------
Decreased Hip Adductor Strength and Obturator Nerve Palsy After the Modified Stoppa Approach to Acetabular Fracture Reduction and Fixation: Is Retraction to Blame?

Conditions
-----------------
Acetabular Fracture, Pelvic Fracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inclusion criteria for the subject patient population under study consists of male and female adults, at least 18 years old, who had an acetabular fracture that was treated with the modified Stoppa approach. Inclusion criteria for the control patient population under study consists of male and female adults, at least 18 years old, who had acetabular fractures with similar fracture patterns as the study group that were treated with any other approach than the Stoppa approach. Exclusion Criteria: Exclusion criteria for the subject and control patient population consist of: Patients who are non-ambulatory. Patients less than 18 years of age. Patients who do not speak English. Patients who are unable to complete their follow-up in Utah.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Outpatient physical therapy strength testing will be used to assess hip adductor strength in all participants (subjects and controls). |  | 1 year follow-up after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiographs and clinical assessment at follow-up appointments will be used to determine incidence of obturator nerve palsy in both groups (subjects and controls). |  | 1 year follow-up after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acetabular fracture, pelvic fracture, hip adductor strength, obturator nerve palsy, modified Stoppa approach
Strigolactones and Dysplastic Colonic Lesions or Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effects of the plant hormones strigolactones, on cell cultures of colonic polyps and colorectal cancer.

Detailed Description
-----------------
Strigolactones have been shown to anti-proliferative and pro-apoptotic effects in cell cultures of breast and prostate origin, partially by down-regulation of cyclin B1 and induction of cell cycle arrest. In this study the investigators intend to take biopsies from benign colonic polyps and cancer tissue, culture intestinal explants and generate immortalized primary cells as a platform to assess the effect of this plant hormone on cell viability, cell mobility, apoptosis and cytoskeleton modifications.

Official Title
-----------------
The Effect of the Plant Hormones Strigolactones on Cultures of Dysplastic Colonic Lesions and Cancer

Conditions
-----------------
Colonic Neoplasms, Colonic Polyps

Intervention / Treatment
-----------------
* Procedure: biopsy during colonoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with positive findings during colonoscopy Exclusion Criteria: Patients below 18 years old Patients who cannot sign a consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| adenoma group<br>Patients with adenoma. Biopsies are taken before endoscopic resection. | Procedure: biopsy during colonoscopy<br>* sampling the lesion with forcept biopter<br>|
| cancer group<br>Patients with colorectal cancer. Biopsies are taken before surgical resection. | Procedure: biopsy during colonoscopy<br>* sampling the lesion with forcept biopter<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of cells with reduced viability after dose-dependent exposure |  | 24 hours of exposure to strigolactone | 
| percentage of cells in G2/M arrest after dose-dependent exposure | analysis of cell cycle | 24 hours of exposure to strigolactone |
Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is determine whether point of care coagulation testing is able to map the anticoagulatory effects of new oral anticoagulants dabigatran and rivaroxaban. Used as devices are thrombelastometry/-graphy (ROTEM, TEG)and multiple platelet function analyzer (Multiplate).

Detailed Description
-----------------
Patients receiving dabigatran or rivaroxaban in therapeutic doses are recruited. Blood will be taken twice in correlation to the time of drug intake (before and 3 hours after drug intake). The results of thrombelastometry/-graphy and multiple platelet function analyzer will be compared directly with the concentrations determined by plasma concentration assays.

Official Title
-----------------
Monitoring The Anticoagulatory Effects of Dabigatran and Rivaroxaban On Plasmatic and Cellular Coagulation by Rotational Thrombelastometry/-Graphy and Multiple Platelet Function Analyzer

Conditions
-----------------
Clot Formation and Platelet Aggregation in Point of Care Testing

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients receiving Dabigatran or Rivaroxaban Adults > 18 years Exclusion Criteria: Patients receiving concomittantly inhibitors of platelet function Renal insufficiency (Creatinine > 1,5 mg/dl), Urea > 80 mg/dl) Hemodialysis Hepatic Dysfunction (AST > 30 U/l, ALT > 30 U/l)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
New Oral Anticoagulants, Dabigatran, Rivaroxaban, Thrombelastometry/-graphy (ROTEM, TEG), Multiple Platelet Function Analyzer (Multiplate)
The Clinical Characteristics of the Patients With Choledocholithiasis Without Cholangitis

Study Overview
=================
Brief Summary
-----------------
Laboratory change induced by common bile duct (CBD) stone is in general observed as the higher elevation of alkaline phosphatase (ALP) and gamma-glutamyl transpeptideas (ɤ-GT), in comparison to those of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). However, some patients with CBD stone show the marked increased level of aminotransferase, which sometimes leads to misdiagnose those as liver disease caused by viral hepatitis, ischemia, and drug toxicity. The aim of this study is to investigate the clinicopathologic features of patients with CBD stones with the high level of aminotransferase in serum.

Official Title
-----------------
The Clinical Characteristics of the Patients With Choledocholithiasis Without Cholangitis Showing the High Level of Aminotransferase and the Establishment of New Nomenclature ; Gallstone Hepatitis

Conditions
-----------------
Choledocholithiasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients were diagnosed with CBD stone under endoscopic retrograde cholangiopancreatography (ERCP) patients showing above 400 IU/L of aminotransferase when at the first admitted into hospital and the control groups is the patients displaying normal AST and ALT. Exclusion Criteria: 1. underlying hepatobiliary disease 2. alcoholics 3. cholangitis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| gallstone hepatitis group,<br>gallstone hepatitis group (Among patients diagnosed as CBD stone who displayed above 400 IU/L of aminotransferase without cholangitis), | |
| control group<br>control group (Among patients diagnosed as CBD stone who showed the normal value of aminotransferase) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinicopathologic features of patients with CBD stones with the high level of aminotransferase | lab finding, radiologic images, and findings under ERCP such as CBD diameter, CBD stone diameter, CBD stone number, periampullary diverticulum. | 1year |
Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients

Study Overview
=================
Brief Summary
-----------------
efficacy and safety of Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,

Detailed Description
-----------------
The study aims to assess Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,

Official Title
-----------------
Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients: A Randomized Controlled Trial.

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Drug: Sofosbuvir
* Drug: Daclatasvir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COVID 19 positive patients Exclusion Criteria: COVID-19 patients with critical manifestations. Sepsis. Acute respiratory distress syndrome (ARDS). Decompensated liver disease (Child-Pugh class B or C disease). Chronic renal impairment. Patients with blood diseases (severe anemia, thalassemia, ITP, leukemia ….). Ischemic heart disease within the last 6 months. Chronic pulmonary disease. Malignancy. Pregnancy or breastfeeding. Hypersensitivity to sofosbuvir or ribavirin. Patients with organ transplant. Unwilling to participate in our study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sofosbuvir and Daklatasuvir<br>Sofosbuvir and Daklatasuvir with standard of care treatment | Drug: Sofosbuvir<br>* Sofosbuvir once daily<br>* Other names: Mpiviropack, Sovaldy, soflanork;Drug: Daclatasvir<br>* daclatasuvir once daily<br>* Other names: daklinza, daklanork;|
| No Intervention: Standard of care treatment<br>Standard of care treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with improvement or mortality | The number of patients with improvement or mortality | 1 month |